PharmacoEconomics & Outcomes News 680 - 15 Jun 2013 Ireland passes Bill on reference pricing, increased generic use The Irish Health (Pricing and Supply of Medical Goods) Bill 2012 has been passed through both Houses of the Oireachtas (the Irish parliament) and now only requires the President’s signature to become operational. Currently in Ireland when a specific brand of medicine is prescribed for a patient, the pharmacist can only supply that particular brand – even when less expensive generic versions are available. The Bill will now allow pharmacists to substitute medicines which have been designated as interchangeable by the Irish Medicines Board. The Bill also outlines reference pricing whereby the Health Service Executive will pay for medicines supplied to patients under the General Medical Services and community drug schemes. If the patient wants a particular brand that costs more than the reference price then the patient will have to pay the additional cost of that product. However, if substitution is prohibited for clinical reasons, patients will not face any additional costs if the prescribed product costs more than the reference price. Welcoming the Bill, Minister for Health, Dr James Reilly said that it will "promote price competition and deliver lower medicine prices for both the State and patients". Department of Health - Ireland. Passing of the Health (Pricing and Supply of Medical Goods) Bill 2012. Media Release : 22 May 2013. Available from: URL: http://www.dohc.ie 809150283 1 PharmacoEconomics & Outcomes News 15 Jun 2013 No. 680 1173-5503/10/0680-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Ireland passes Bill on reference pricing, increased generic use

Download PDF Report

Upload
lillian-turner
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 680 - 15 Jun 2013

Ireland passes Bill on referencepricing, increased generic use

The Irish Health (Pricing and Supply of MedicalGoods) Bill 2012 has been passed through both Housesof the Oireachtas (the Irish parliament) and now onlyrequires the President’s signature to becomeoperational.

Currently in Ireland when a specific brand of medicineis prescribed for a patient, the pharmacist can onlysupply that particular brand – even when less expensivegeneric versions are available. The Bill will now allowpharmacists to substitute medicines which have beendesignated as interchangeable by the Irish MedicinesBoard.

The Bill also outlines reference pricing whereby theHealth Service Executive will pay for medicines suppliedto patients under the General Medical Services andcommunity drug schemes. If the patient wants aparticular brand that costs more than the reference pricethen the patient will have to pay the additional cost ofthat product. However, if substitution is prohibited forclinical reasons, patients will not face any additionalcosts if the prescribed product costs more than thereference price.

Welcoming the Bill, Minister for Health, Dr JamesReilly said that it will "promote price competition anddeliver lower medicine prices for both the State andpatients".Department of Health - Ireland. Passing of the Health (Pricing and Supply ofMedical Goods) Bill 2012. Media Release : 22 May 2013. Available from: URL:http://www.dohc.ie 809150283